Nephrotic syndrome caused by immune-mediated acquired LCAT deficiency

Journal of the American Society of Nephrology

Volumn 24, Issue 8, 2013, Pages 1305-1312

  Takahashi, Satoshi ^a   Hiromura, Keiju ^a   Tsukida, Mayuko ^a   Ohishi, Yuko ^a   Hamatani, Hiroko ^a   Sakurai, Noriyuki ^a   Sakairi, Toru ^a   Ikeuchi, Hidekazu ^a   Kaneko, Yoriaki ^a   Maeshima, Akito ^a   Kuroiwa, Takashi ^a   Yokoo, Hideaki ^a   Aoki, Takeo ^a   Nagata, Michio ^b   Nojima, Yoshihisa ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; HIGH DENSITY LIPOPROTEIN; NEUROLEPTIC AGENT; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PREDNISOLONE; STEROID;

ADULT; ARTICLE; CASE REPORT; DRUG DOSE REDUCTION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FOAM CELL; GLOMERULUS CAPILLARY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KIDNEY BIOPSY; KIDNEY PARENCHYMA; LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; MEMBRANOUS GLOMERULONEPHRITIS; MICROSCOPY; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; REMISSION; WESTERN BLOTTING;

EID: 84881100717     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2012090913     Document Type: Article

References (21)

1. Jonas A: Lecithin cholesterol acyltransferase. Biochim Biophys Acta 1529: 245-256, 2000
2. Zannis VI, Chroni A, Krieger M: Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med (Berl) 84: 276-294, 2006
3. Calabresi L, Franceschini G: Lecithin:cholesterol acyltransferase, highdensity lipoproteins, and atheroprotection in humans. Trends Cardiovasc Med 20: 50-53, 2010
4. GjoneE, NorumKR: Familial serumcholesterolesterdeficiency. Clinical study of a patientwith a newsyndrome. Acta Med Scand 183: 107-112, 1968
5. Carlson LA, Philipson B: Fish-eye disease. A new familial condition with massive corneal opacities and dyslipoproteinaemia. Lancet 2: 922-924, 1979
6. Dalrymple LS, Kaysen GA: The effect of lipoproteins on the development and progression of renal disease. Am J Nephrol 28: 723- 731, 2008
7. Calabresi L, Pisciotta L, Costantin A, Frigerio I, Eberini I, Alessandrini P, ArcaM, Bon GB, Boscutti G, Busnach G, Frascà G, Gesualdo L, Gigante M, Lupattelli G, Montali A, Pizzolitto S, Rabbone I, RolleriM, Ruotolo G, Sampietro T, Sessa A, Vaudo G, Cantafora A, Veglia F, Calandra S, Bertolini S, Franceschini G: The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: A comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler Thromb Vasc Biol 25: 1972-1978, 2005
8. Rousset X, Vaisman B, Amar M, Sethi AA, Remaley AT: Lecithin: cholesterol acyltransferase-from biochemistry to role in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 16: 163-171, 2009
9. Fogo A, Kashgarian M: Lecithin-cholesterol acyltransferase deficiency. In: Diagnostic Atlas of Renal Pathology, Philadelphia, PA, Elsevier Saunders, 2005, pp 171-174
10. Simonelli S, Gianazza E, Mombelli G, Bondioli A, Ferraro G, Penco S, Sirtori CR, Franceschini G, Calabresi L: Severe high-density lipoprotein deficiency associated with autoantibodies against lecithin:cholesterol acyltransferase in non-Hodgkin lymphoma. Arch Intern Med 172: 179- 181, 2012
11. Sato H, Ito S, Akiu N: A case of nephrotic syndrome with lecithin cholesterol acyltransferase deficiency that was improved by steroid therapy (in Japanese). Ther Res 23: 1329-1330, 2002
12. Appel GB, Radhakrishnan J, D'Agati V: Secondary glomerular disease. In: The Kidney, edited by Brenner BM, 6th Ed., Philadelphia, WB Saunders, 2000, pp 1350-1448
13. Steinberg D: Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime. Nat Med 8: 1211-1217, 2002
14. Tall AR, Wang N: Tangier disease as a test of the reverse cholesterol transport hypothesis. J Clin Invest 106: 1205-1207, 2000
15. Tanigawa H, Billheimer JT, Tohyama J, Fuki IV, Ng DS, Rothblat GH, Rader DJ: Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. Circulation 120: 160-169, 2009
16. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11-21, 2009
17. Prunotto M, Carnevali ML, Candiano G, Murtas C, BruschiM, Corradini E, Trivelli A, Magnasco A, Petretto A, Santucci L, Mattei S, Gatti R, Scolari F, Kador P, Allegri L, Ghiggeri GM: Autoimmunity in membranous nephropathy targets aldose reductase and SO D2. J Am Soc Nephrol 21: 507-519, 2010
18. Panescu V, Grignon Y, Hestin D, Rostoker G, Frimat L, Renoult E, Gamberoni J, Grignon G, Kessler M: Recurrence of lecithin cholesterol acyltransferase deficiency after kidney transplantation. Nephrol Dial Transplant 12: 2430-2432, 1997
19. Brady RO: Enzyme replacement for lysosomal diseases. Annu RevMed 57: 283-296, 2006
20. Rousset X, Vaisman B, Auerbach B, Krause BR, Homan R, Stonik J, Csako G, Shamburek R, Remaley AT: Effect of recombinant human lecithin cholesterol acyltransferase infusion on lipoprotein metabolism in mice. J Pharmacol Exp Ther 335: 140-148, 2010
21. Kuroda M, Bujo H, Aso M, Saito Y: Adipocytes as a vehicle for ex vivo gene therapy: Novel replacement therapy for diabetes and other metabolic diseases. J Diabetes Investig 2: 333-340, 2011